TSG Brings Bioscience Brand To Life

We're happy to be finishing up a new integrated marketing communications exercise for ReGenX, a Washington, DC-based bioscience startup. ReGenX is a biologics company focused on the development of gene therapy as a platform for advancing human health. (Read more about biologics HERE)

The company produces a type of proprietary viral vector, which is a microscopic tool that molecular biologists use to transfer different kinds of genetic material into cells. This transfer allows for advances in biotherapeautics, drug discovery, vaccines, target identification and target validation. These are all REALLY important things for fighting disease.

Our goal for ReGenX was two-fold: First, we wanted to clearly establish ReGenX as a reputable player in the cellular biology space. We accomplished this by crafting a brand identity that established credibility and clearly spoke to the company's purpose and service offerings, in addition to linking the company to technological developments from the University of Pennsylvania and a team of well-respected scientific advisors.



We also wanted to create a range of consistent, polished marketing materials that makes it easy for cellular biologists to understand ReGenX's product offerings and provide a clear path to purchase. One of the key tools we created was http://www.regenxbio.com. Clean design, simple navigation and well-organized content converge to allow users to easily find their desired information and the integration of a NetSuite enabled form allows them to easily request a quote.






We're extremely proud of the work we've done for ReGenX and look forward to continuing to support them. Interested in finding out how we can help you craft a new brand from scratch or reenergize an existing brand? We'd love to talk.

by Garret Ohm

Leave a Comment

You are not logged in, so a moderator will need to approve your comment before it appears on this page.

Name:

Email:

Notify me of follow-up comments?

Please enter the word you see in the image below:

Comments

There are no comments for this entry yet.